High expression of Cathepsin D in Non-Hodgkin's Lymphomas negatively impacts on clinical outcome

Disease Markers

Volumn 28, Issue 3, 2010, Pages 167-183

  Nicotra, Giuseppina ^a   Manfroi, Federica ^a   Follo, Carlo ^a   Castino, Roberta ^a   Fusco, Nicola ^a   Peracchio, Claudia ^a   Kerim, Simonetta ^b   Valente, Guido ^a   Isidoro, Ciro ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Cathepsin D; lymphomas; prognosis; tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN D;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; EMBEDDING; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYSOSOME; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TUMOR CELL;

EID: 77954092171     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0698     Document Type: Article

References (31)

1. S.A Pileri, S. Ascani, E. Sabattini, G. Fraternali-Orcioni, S. Poggi, M. Piccioli, P.P. Piccaluga, B. Gamberi, P.L. Zinzani, L. Leoncini and B. Falini, The pathologist's view point. Part I- indolent lymphomas, Haematologica 85 (2000), 1291-1307. (Pubitemid 32063700)
2. S.A. Pileri, S. Ascani, E. Sabattini, G. Fraternali-Orcioni, S. Poggi, M. Piccioli, P.P. Piccaluga, B. Gamberi, P.L. Zinzani, L. Leoncini and B. Falini, The pathologist's view point. Part II - aggressive lymphomas, Haematologica 85 (2000), 1308-1321. (Pubitemid 32063701)
3. N. Niitsu, H. Nakamine, M. Okamoto, H. Akamatsu, M. Higashihara, Y. Honma, J. Okabe-Kado and M. Hirano, Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma, Clin Cancer Res 10 (2004), 2482-2490.
4. B. Petit, M.P. Chaury, C. Le Clorennec, A. Jaccard, N. Gachard, S. Moalic-Judge, F. Labrousse, M. Cogńe, D. Bordessoule and J. Feuillard, Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup, Haematologica 90 (2005), 200-206.
5. P.L. Zinzani, S. Dirnhofer, E. Sabattini, L. Alinari, P.P. Piccaluga, V. Stefoni, M. Tani, G. Musuraca, E. Marchi, B. Falini, M. Baccarani and S.A. Pileri, Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays, Haematologica 90 (2005), 341-347.
6. M.B. Valnet-Rabier, B. Challier, S. Thiebault, R. Angonin, G. Margueritte, C. Mougin, B. Kantelip, E. Deconinck, J.Y. Cahn and T. Fest, c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome, Br J Haematol 128 (2005), 767-773.
7. G. Valente, F. Manfroi, C. Peracchio, G. Nicotra, R. Castino, G. Nicosia, S. Kerim and C. Isidoro, cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy, Br J Haematol 132 (2006), 560-570.
8. A. Troeger, M. Siepermann, G. Escherich, R. Meisel, R. Willers, S. Gudowius, T. Moritz, H.J. Laws, H. Hanenberg, U. Goebel, G.E. Janka-Schaub, C. Mahotka and D. Dilloo, Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia, Haematologica 92 (2007), 1043-1050. (Pubitemid 350144210)
9. D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, F. Forconi, F. Lauria and G. Gaidano, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness, Clin Cancer Res 15 (2009), 995-1004.
10. P. Saftig, M. Hetman, W. Schmahl, K. Weber, L. Heine, H. Mossmann, A. Köster, B. Hess, M. Evers and K. von Figura, Mice deficient for the lysosomal proteinase cathepsinDexhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells, EMBO J 1 (1995), 3599-3608.
11. G.S. Wu, P. Saftig, C. Peters and W.S. El-Deiry, Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity, Oncogene 16 (1998), 2177-2183.
12. L. Emert-Sedlak, S. Shangary, A. Rabinovitz, M.B. Miranda, S.M. Delach and D.E. Johnson, Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death, Mol Cancer Ther 4 (2005), 733-742.
13. N.F. Trincheri, G. Nicotra, C. Follo, R. Castino and C. Isidoro, Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D, Carcinogenesis 28 (2007), 922-931.
14. R. Castino, C. Peracchio, A. Salini, G. Nicotra, N.F. Trincheri, M. D́emoz, G. Valente and C. Isidoro, Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop, J Cell Mol Med 13 (2008), 1096-1109.
15. L.P. Deiss, H. Galinka, H. Berissi, O. Cohen and A. Kimchi, Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha, EMBO J 15 (1996), 3861-3870.
16. M. D́emoz, R. Castino, P. Cesaro, F.M. Baccino, G. Bonelli and C. Isidoro, Endosomal-lysosomal proteolysis mediates death signalling by TNFalpha, not by etoposide, in L929 fi- brosarcoma cells: evidence for an active role of cathepsin D, Biol Chem 383 (2002), 1237-1248.
17. V. Vetvicka and M. Fusek, Activation of peripheral blood neutrophils and lymphocytes by human procathepsin D and insulin-like growth factor II, Cell Immunol 156 (1994), 332-341.
18. V.Vaclav, V. Jana and F. Martin, Participation of the propeptide on procathepsinDactivation of human peripheral lymphocytes and neutrophils, Arch Biochem Biophys 10 (1995), 295-298.
19. E.S. Jaffe, N.L. Harris and H. Stein, World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue, IARC, Lyon, France, 2001.
20. E.L. Kaplan and P. Meier, Nonparametric estimation from incomplete observations, Journal of the American Statistical Association 53 (1958), 457-481.
21. D.R. Cox, Regression models and life-tables, JR Stat Soc (B) 34 (1972), 187-202.
22. M. Namer, A. Ramaioli, X. Fontana, M.C. Etienne, M. H́ery, A. Jourlait, G. Milano, M. Frenay, E. François and F. Lapalus, Prognostic value of total cathepsin Din breast tumors. Apossible role in selection of chemoresistant patients, Breast Cancer Res Treat 19 (1991), 85-93.
23. H. Allgayer, R. Babic, K.U. Grützner, B.C. Beyer, A. Tarabichi, A. Wilhelm, F. Schildberg and M.M. Heiss, An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis, Cancer 80 (1997), 179-187.
24. C. Charpin, S. Garcia, C. Bouvier, F. Martini, M. Lavaut, C. Allasia, P. Bonnier and L. Andrac, Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival, J Clin Pathol 50 (1997), 586-590. (Pubitemid 27359517)
25. T.T. Lah, M. Cercek, A. Blejec, J. Kos, E. Gorodetsky, R. Somers and I. Daskal, Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators, Clin Cancer Res 6 (2000), 578-584.
26. T.T. Lah, E. Kalman, D. Najjar, E. Gorodetsky, P. Brennan, R. Somers and I. Daskal, Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis, Hum Pathol 31 (2000), 149-160.
27. A.C. Lazaris, I. Lendari, N. Kavantzas, D. Kandiloros, G. Adamopoulos and P. Davaris, Correlation of tumor markers p53, bcl-2 and cathepsin-D with clinicopathologic features and disease-free survival in laryngeal squamous cell carcinoma, Pathol Int 50 (2000), 717-724.
28. M. Ikeguchi, T. Sakatani, T. Ueta, K. Fukuda, K. Yamaguchi, S. Tsujitani and N. Kaibara, Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma, J Clin Pathol 55 (2002), 121-126. (Pubitemid 34123913)
29. A. Lösch, M. Schindl, P. Kohlberger, J. Lahodny, G. Breitenecker, R. Horvat and P. Birner, Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density, Gynecol Oncol 92 (2004), 545-552.
30. A.L. Cheng, W.G. Huang, Z.C. Chen, P.F. Zhang, M.Y. Li, F. Li, J.L. Li, C. Li, H. Yi, F. Peng, C.J. Duan and Z.Q. Xiao, Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis, J Proteome Res 7 (2008), 2415-2426.
31. J. Linderoth, P. Ed́en, M. Ehinger, J. Valcich, M. Jerkeman, PO. Bendahl, M. Berglund, G. Enblad, M. Erlanson, G. Roos and E. Cavallin-Sthl, Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma, Br J Haematol 141 (2008), 423-432.